Biohaven Ltd.
NYSE · BHVN·New Haven, CT·Small-cap·Phase 2
Biopharmaceutical company with a broad portfolio spanning immunology, neuroscience, and oncology. Proprietary MoDE and TRAP degrader platforms power priority programs including BHV-1300 (IgG degrader for Graves' disease) and BHV-1400 (Gd-IgA1 TRAP for IgA nephropathy), with pivotal trials expected by mid-2026.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Biohaven Corporate Presentation January 2026 | Corporate overview | January 1, 2026 | 87 |